Abstract
Nasal septum perforation in patients with cancer receiving systemic therapy is rare, and its association with bevacizumab use has described recently in the literature. Here, we report the case of a 34-year-old woman with hormone-sensitive, HER-2/neu negative, metastatic breast cancer who develope a nasal septum perforation during the treatment with paclitaxel and bevacizumab.
Keywords:
bevacizumab; breast cancer; nasal septum perforation.
© 2017 Wiley Periodicals, Inc.
MeSH terms
-
Adult
-
Angiogenesis Inhibitors / administration & dosage
-
Angiogenesis Inhibitors / adverse effects
-
Antibodies, Monoclonal, Humanized / administration & dosage
-
Antibodies, Monoclonal, Humanized / adverse effects
-
Antineoplastic Combined Chemotherapy Protocols / adverse effects*
-
Bevacizumab / administration & dosage
-
Bevacizumab / adverse effects
-
Breast Neoplasms / drug therapy*
-
Breast Neoplasms / pathology
-
Diagnosis, Differential
-
Female
-
Humans
-
Lung Neoplasms / drug therapy*
-
Lung Neoplasms / secondary
-
Nasal Septal Perforation / chemically induced
-
Nasal Septal Perforation / diagnosis*
-
Neoplasm Metastasis
-
Paclitaxel / administration & dosage
-
Paclitaxel / adverse effects
Substances
-
Angiogenesis Inhibitors
-
Antibodies, Monoclonal, Humanized
-
Bevacizumab
-
Paclitaxel